Related references
Note: Only part of the references are listed.Biological Therapies for Atopic Dermatitis: A Systematic Review
Shuying Zhou et al.
DERMATOLOGY (2021)
Current and future status of JAK inhibitors
Donal P McLornan et al.
LANCET (2021)
Updates and new medical treatments for vitiligo (Review)
David Emmanuel Kubelis-Lopez et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Cutaneous JAK Expression in Vitiligo
Amira A. Abdel Motaleb et al.
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY (2021)
Vitiligo: Mechanisms of Pathogenesis and Treatment
Michael L. Frisoli et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 38 (2020)
Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo
P. Mobasher et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth B. Forman et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael F. Robinson et al.
ARTHRITIS & RHEUMATOLOGY (2020)
Repigmentation of vitiligo with oral baricitinib
Blake P. Mumford et al.
AUSTRALASIAN JOURNAL OF DERMATOLOGY (2020)
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo
Nesrine Boukhedouni et al.
JCI INSIGHT (2020)
Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial
David Rosmarin et al.
LANCET (2020)
Vitiligo, From Physiopathology to Emerging Treatments: A Review
Laure Migayron et al.
DERMATOLOGY AND THERAPY (2020)
Vitiligo and anxiety: A systematic review and meta-analysis
Assiya Kussainova et al.
PLOS ONE (2020)
Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs
Indushekhar Persaud et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2020)
Oxidative stress-induced IL-15 trans-presentation in keratinocytes contributes to CD8+ T cells activation via JAK-STAT pathway in vitiligo
Xuguang Chen et al.
FREE RADICAL BIOLOGY AND MEDICINE (2019)
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
Greg P. Coffey et al.
CLINICAL CANCER RESEARCH (2019)
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Nawaf Almutairi et al.
DERMATOLOGY (2019)
Comorbidities in vitiligo: comprehensive review
Aisha M. Dahir et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)
Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3
Katia Boniface et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B
Deep Joshipura et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose. Narrowband UV-B Phototherapy
Sa Rang Kim et al.
JAMA DERMATOLOGY (2018)
Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study
Hanan Rabea Nada et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2018)
Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease
Jillian M. Richmond et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
CXCR3 Depleting Antibodies Prevent and Reverse Vitiligo in Mice
Jillian M. Richmond et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Current and emerging treatments for vitiligo
Michelle Rodrigues et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
Lucy Y. Liu et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity
James P. Strassner et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib
Brooke Rothstein et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2017)
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
P. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment of Alopecia Areata With Tofacitinib
Omer Ibrahim et al.
JAMA DERMATOLOGY (2017)
Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by type I Interferons and viral Antagonism
Yuchen Nan et al.
FRONTIERS IN IMMUNOLOGY (2017)
Heat shock protein 70 potentiates interferon alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis
C. Jacquemin et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Vitiligo and depression: a systematic review and meta-analysis of observational studies
Y. C. Lai et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
Shubhasree Banerjee et al.
DRUGS (2017)
Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo
X. X. Wang et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool
Camille Salzes et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)
John E. Harris et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Julian Mackay-Wiggan et al.
JCI INSIGHT (2016)
The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
John J. O'Shea et al.
ANNUAL REVIEW OF MEDICINE, VOL 66 (2015)
Tofacitinib Citrate for the Treatment of Vitiligo A Pathogenesis-Directed Therapy
Brittany G. Craiglow et al.
JAMA DERMATOLOGY (2015)
Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Luzhou Xing et al.
NATURE MEDICINE (2014)
Type I interferon signature in the initiation of the immune response in vitiligo
Antoine Bertolotti et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
CXCL10 Is Critical for the Progression and Maintenance of Depigmentation in a Mouse Model of Vitiligo
Mehdi Rashighi et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer
Greg Coffey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
Annkristin Heine et al.
BLOOD (2013)
Metalloproteinases and their natural inhibitors in inflammation and immunity
Rama Khokha et al.
NATURE REVIEWS IMMUNOLOGY (2013)
A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-γ for Autoreactive CD8+ T-Cell Accumulation in the Skin
John E. Harris et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2012)
Ruxolitinib
Ruben A. Mesa et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Vitiligo: A comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up
Ali Alikhan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2011)
Trans-presentation: A novel mechanism regulating IL-15 delivery and responses
Spencer W. Stonier et al.
IMMUNOLOGY LETTERS (2010)
Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients
Jasper G. van den Boorn et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Mechanisms of type-I- and type-II-interferon-mediated signalling
LC Platanias
NATURE REVIEWS IMMUNOLOGY (2005)
Topical tacrolimus therapy for vitiligio: Therapeutic responses and skin messenger RNA expression of proinflammatory cytokines
PE Grimes et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2004)
Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo
A Wankowicz-Kalinska et al.
LABORATORY INVESTIGATION (2003)
Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers:: the role of cellular immunity in the etiopathogenesis of vitiligo
B Palermo et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Janus kinases: components of multiple signaling pathways
SG Rane et al.
ONCOGENE (2000)
Share Paper
